Progenity rises on U.S. patent for preeclampsia risk test

PROG Holdings

14/09/2021 14:28

** Shares of medical diagnostics company  PROG.O  jump 14.9%
to $1.08 premarket
    ** PROG receives a U.S. patent for its test to evaluate
patients who have signs and symptoms of possible preeclampsia
 urn:newsml:reuters.com:*:nGNX9gbrNh
    ** Preeclampsia is a pregnancy complication with symptoms
including high blood pressure and damage to organs such as liver
and kidneys
    ** Co's Preecludia test is designed to study biomarkers to
detect risk of preeclampsia and can be run from a simple blood
draw
    ** Preeclampsia symptoms appear in up to 30% of pregnant
women in the United States, according to PROG
    ** PROG down 82.3% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))